Myelin basic protein (MBP) may be an important autoantigen in multiple sclerosis (MS), with the MBP(82-100) region being immunodominant for T cells and autoantibodies. The structural requirements for autoantibody recognition were compared to those previously defined for MBP-specific T cell clones. MBP autoantibodies were affinity-purified from central nervous system lesions of 11/12 postmortem cases studied. The MBP(83-97) peptide was immunodominant in all 11 cases since it inhibited autoantibody binding to MBP > 95%. Residues contributing to autoantibody binding were located in a 10-amino acid segment (V86-T95) that also contained the MHC/T cell receptor contact residues of the T cell epitope. In the epitope center, the same residues were important for antibody binding and T cell recognition. Based on the antibody-binding motif, microbial peptides were identified that were bound by purified autoantibodies. Autoantibody binding of microbial peptides required sequence identity at four or five contiguous residues in the epitope center. Microbial peptides previously found to activate T cell clones did not have such obvious homology to MBP since sequence identity was not required at MHC contacts. The similar fine specificity of B cells and T cells may be useful for tolerance induction to MBP in MS.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) 1 myelin. The inflammatory process is characterized by focal infiltration of T cells, B cells, and macrophages, and by a loss of myelin (1) . Several lines of evidence indicate that myelin basic protein (MBP), an abundant protein component of myelin, is a target antigen for T cells and autoantibodies in MS. The immunodominant T cell epitope was localized to residues 82-100 of MBP; this MBP peptide binds with high affinity to the disease-associated HLA-DR2 molecule, and is recognized by HLA-DR2-restricted T cell clones from MS patients. The MBP(82-100) peptide contains an epitope for DR2 (DRA, DRB1*1501)-restricted T cells as well as an epitope for T cells restricted by other DR antigens (2) (3) (4) (5) (6) (7) (8) (9) . The same region of human MBP is also immunodominant for MBP-specific autoantibodies purified from the CNS white matter of MS patients. The epitope for tissuebound autoantibody was localized to residues 82-99 of MBP, while the epitope for free, unbound antibody was localized to residues 75-106 (10) (11) (12) (13) (14) (15) (16) .
MBP-specific B cells have been immunolocalized in MS lesions, and local synthesis of MBP-specific autoantibodies in the CNS of MS patients has been demonstrated (17, 13) . Tissue infiltration by MBP-specific T cells and B cells may be important in the autoimmune response against MBP. Antigenspecific B cells are efficient antigen-presenting cells, since they internalize antigen through surface immunoglobulin (18, 19) . The cognate interaction of antigen-specific B cells and T cells results in the activation of CD4 ϩ T cells; activated T cells in turn enhance antibody production by B cells through cognate interactions (CD40-CD40 ligand) and the secretion of cytokines (20, 21) . B cell-T cell collaboration may therefore result in the simultaneous expansion of MBP-specific T cells and B cells in MS lesions. MBP-specific autoantibodies may also enhance Fc receptor-mediated phagocytosis and presentation of MBP or myelin by macrophages.
In this paper, the fine specificity of MBP autoantibodies was examined using antibodies that were affinity-purified from postmortem CNS tissue of eleven MS cases. Peptide residues that were critical for autoantibody binding were identified, allowing a detailed comparison to the T cell epitope that was previously characterized. The antibody recognition motif was used to identify viral and bacterial peptides that were bound by affinity-purified MBP-specific autoantibodies. A peptide from human papillomavirus that was previously found to activate a human MBP-specific T cell clone was bound by autoantibodies from all MS patients studied. These results demonstrate that MBP-specific autoantibodies have a remarkably similar fine specificity for the immunodominant peptide of human myelin basic protein.
Methods

Purification of MBP autoantibodies from postmortem MS brain tissue.
Tissue-bound MBP-specific autoantibodies were purified from postmortem CNS tissue by affinity chromatography, as previously described (13) . In brief, CNS tissue was cut into thin slices, washed extensively with saline, and then homogenized in 0.01 M PBS, pH 7.2, containing 0.2% sodium azide, 0.005 M pepstatin and 0.004 M ⑀ -aminocaproic acid. The homogenate was centrifuged at 100,000 g and tissue-bound antibodies were released by resuspending the pellet in 0.1 M glycine-HCl, pH 2.2, containing 0.05 M ⑀ -amino-caproic acid and 0.2% sodium azide. After a 1-h incubation, the samples were centrifuged at 100,000 g , and the supernatant was neutralized. IgG was purified from these neutralized supernatants by protein A or protein G affinity chromatography (Protein A or Protein G Sepharose 4 Fast Flow; Pharmacia Diagnostics AB, Uppsala, Sweden). After elution of IgG from the protein A or protein G column, antibodies were immediately neutralized and dialyzed. Purified IgG migrated as a single band on SDS-PAGE under nonreducing conditions, and as heavy and light chains under reducing conditions. MBP affinity chromatography was used to purify MBP-specific antibodies from the IgG fraction. MBP was purified from human brain and coupled to CNBr-activated Sepharose 4B beads (Pharmacia Diagnostics AB). Purified IgG was loaded on the MBP affinity column, the column was washed with 0.02 M phosphate buffer, pH 7.0, and MBP-specific antibodies were eluted with 0.1 M glycine-HCl, pH 2.2. After elution, purified antibodies were immediately neutralized and concentrated after dialysis. Protein purity was assessed by SDS-PAGE.
Analysis of antibody binding. The specificity of purified MBP autoantibodies was examined in a solid-phase radioimmunoassay; synthetic peptides in the liquid phase were used to compete for the binding of autoantibody to immobilized MBP (13) . To allow for comparison of data from different patients, antibody concentration in the assay was normalized to 10 g/ml of affinity-purified antibody. Immulon microtiter plates were coated with 1 g/well of purified human MBP, and plates were stored at 4 Њ C. Plates were blocked with 1% BSA in 0.05 M barbitol, 0.05 M NaCl, pH 7.2, for 1 h, and were then washed with 0.05 M barbitol, 0.05 M NaCl, 0.05% Tween 20, pH 7.2. For the competition assay, synthetic peptides and purified MBP autoantibodies were mixed at a final concentration of 10 g/ml of antibody, and of 10 g/ml of synthetic peptide for 2 h at room temperature. 100 l (corresponding to 1 g of antibody) were then added to each well of the MBP-coated plates, and incubated at room temperature for 1 h. MBP-bound antibody was detected using an Fc-specific anti-human IgG antibody (ICN Pharmaceuticals, Costa Mesa, CA) (1 h, room temperature), followed by [ 125 I]-labeled protein A (60,000-85,000 cpm/well) (1 h, room temperature). Plates were washed twice with H 2 O; dried, individual wells were broken from the strips and placed in a ␥ -counter.
Binding of MBP-specific autoantibodies to viral and bacterial peptides. Biotinylated peptides were synthesized on pins in a 96-well format (Chiron Mimotopes, San Diego, CA). Peptides were solubilized in 40% acetonitrile, 100 mM Hepes, pH 7.4, at a concentration of 2 mg/ml, and were subjected to matrix-assisted laser desorption mass spectroscopy (Lasermat; Finnigan, San Jose, CA). For the direct binding assay, plates were coated with 1 g/well of streptavidin, and were then blocked with 1% BSA in 0.05 M barbitol, 0.05 M NaCl, pH 7.2, for 1 h. 1 g of biotinylated peptide was added to each well in a 100-l volume (1 h, room temperature), followed by blocking with 1% BSA in barbitol buffer. After washing, purified MBP-specific autoantibody was added (100 l, 10 g/ml) and incubated for 1 h at room temperature. Bound antibody was detected with anti-human IgG, followed by [ 125 I]-labeled protein A as described above.
Results
Definition of MBP peptide residues that are critical for autoantibody binding. MBP-specific autoantibodies were purified from postmortem CNS tissue of 12 MS cases by two-step affinity chromatography. In 10 of the 12 MS cases, the yield of purified autoantibody (after MBP affinity chromatography) was 0.44-0.71 mg of purified autoantibody from ‫ف‬ 2 g of tissue; in one MS case (patient D) the yield was much higher (6.01 mg). MBP autoantibodies constituted 13.8-18.4% of the total IgG in 10 of the MS cases, and 46.5% of the total IgG in patient D. From one of the samples, no purified MBP autoantibody was obtained. Two different radioimmunoassays were used to examine the specificity of purified autoantibodies. In the first assay, antibody binding to immobilized human MBP was examined (Figs. 1 and 2); in the second assay, biotinylated peptides were captured on streptavidin-coated plates (Table I) .
A previous study had demonstrated that tissue-bound, MBP-specific autoantibodies that were purified from the CNS white matter of a MS patient were specific for the MBP(82-99) peptide (16) . The MBP(83-97) peptide (ENPVVHFFKNIV-TPR) and a panel of alanine analogs of MBP(83-97) were used to examine the specificity of autoantibodies from the 11 MS cases (Fig. 1 , patients A-J, Fig. 2 b : patient K). In all patients, the MBP(83-97) peptide inhibited binding of affinity-purified autoantibodies to MBP Ͼ 95%, indicating that this epitope was immunodominnant for tissue-bound autoantibodies in all of these patients. Inhibition was specific since substitution of some peptide positions (particularly K91) by alanine ( Fig. 1) , other L -amino acids or D -amino acids (Fig. 2) greatly reduced the ability of peptides to compete for autoantibody binding to MBP.
Peptide residues that contributed to autoantibody binding were located in a 10-amino acid segment between V86 and T95 (ENPVVHFFKNIVTPR) since alanine substitutions in this segment affected the ability of analog peptides to compete for autoantibody binding to MBP. In all patients, the core of the epitope was located between H88 and I93, with the epitope being centered around residues F89, F90, K91, and N92. In 7 of 11 MS cases (patients A-G), substitution of K91 by alanine abrogated antibody binding (Fig. 1) . Substitution of K91 by other L -amino acids or D -lysine (Fig. 2 a , patient A) confirmed that K91 was a key residue. In four other MS cases (patients H-K) (Fig. 1, Fig. 2 b ) , analog peptides of K91 showed a moderate degree of binding to MBP (competition of ‫ف‬ 20%). In these MS patients, peptide positions F89 and F90 represented primary contact residues (Figs. 1-3) .
Comparison of the T cell and autoantibody epitopes. The fine specificity of MBP-specific autoantibodies described above was strikingly similar to that previously established for MBPspecific T cell clones from patients with the disease-associated HLA-DR2 haplotype. These MBP-specific T cell clones recognized a 15-amino acid peptide (MBP 83-97: ENPVVH-FFKNIVTPR) bound to different HLA-DR2 subtypes (DRB1*1501 or DRB1*1602) or to HLA-DQ1 (DQA1*0101, DQB1*0501) (8, 22, 23) . Two different numbering systems have been used for this MBP peptide, corresponding to human MBP (residues 83-97) and the cDNA sequence of porcine MBP (residue 85-99) (16, 2) . In this work, the former numbering system was used, corresponding to that previously used in studies of autoantibodies.
The same 10-amino acid peptide segment that represented the antibody epitope contained the MHC binding/TCR contact residues of the T cell epitope (Fig. 3) . Also, both the antibody and the T cell epitope were centered on the H88-K91 segment, and F89 and K91 were key contact residues both for MBP-specific T cell clones and autoantibodies. Important dif-ferences between the antibody and the T cell epitope were that a 13-15 amino acid peptide was required for optimal stimulation of MBP-specific T cell clones, while autoantibodies bound a 10-amino acid peptide. Also, peptide residues in the center of the antibody epitope (H88, F89, F90, K91) could not be substituted by structurally related amino acids (Fig. 2) . In the T cell epitope, only T cell receptor (TCR), but not MHC contact residues, had to be conserved since MHC contact residues (V87 and F90) could be substituted by other hydrophobic amino acids (8, 22, 24) .
Definition of the peptide motif required for autoantibody binding. The requirements for autoantibody binding to MBP were further examined using a panel of 44 analog peptides with single amino acid substitutions in the VVHFFKNI segment (Fig. 2) . Analysis of autoantibodies from two patients (A and K) demonstrated that the FFK recognition motif in the epitope center had to be fully conserved. Even conservative substitutions of F89 and F90 by other aromatic (Y, W) or by aliphatic residues (V, L, I) greatly reduced the ability of synthetic peptides to compete for autoantibody binding to MBP (Fig. 2) . Autoantibodies from the two patients had a similar fine specificity to this large panel of analog peptides, with a difference in the relative contribution of K91 to antibody binding. These results were confirmed using 10-amino acid peptides with D -amino acid substitutions (Fig. 2) .
Binding of microbial peptides by affinity-purified, MBPspecific autoantibodies. The loss of tolerance in MS may result from a challenge of the immune system by microbial peptides that have sufficient structural similarity with immunodominant T cell and B cell epitopes (24) (25) (26) . Clinical studies on cerebrospinal fluid samples from MS patients have provided evidence for the local synthesis of antibodies in the CNS that react with a diverse group of viral and bacterial antigens, but binding of microbial antigens by purified autoantibodies has not been studied (27, 28) . Microbial peptides that were bound by MBP-specific autoantibodies were identified through a search of the PIR protein database with the HFFK or FFKN motifs, using the program findpatterns of the Genetics Computer Group (Madison, WI) software. A total of 213 sequences from the database met the criteria (145 with the FFKN motif, 68 with the HFFK motif). 23 peptides were synthesized with an NH 2 -terminal biotin and a four-amino acid spacer (SGSG) between the biotin moiety and the 15-amino acid viral/bacterial peptide sequence (Table I) .
Binding of microbial peptides by affinity-purified, MBPspecific autoantibodies was examined in a direct binding assay Figure 1 . Specificity of MBP-specific autoantibodies purified from MS lesions. MBP-specific autoantibodies were purified from CNS white matter of 11 MS cases (patients A-J shown in Fig. 1 , patient K shown in Fig. 2 b) by two-step affinity chromatography. The binding of autoantibodies was examined in a radioimmunoassay in which soluble MBP peptides were used to compete for binding of autoantibodies to immobilized MBP. In all MS cases examined, the MBP(83-97) peptide inhibited binding of autoantibodies to MBP by Ͼ 95%, indicating that this peptide represented the immunodominant segment. The autoantibody epitope was located in a 10-amino acid segment (V86-T95), and was centered around residues H88, F89, F90, K91, and N92. In seven of the patients (A-G), substitution of K91 by alanine resulted in a complete loss of binding to MBP; in four other MS cases, F89 and F90 were key residues. in which biotinylated peptides were captured on a streptavidin-coated plate. Antibody binding was detected using an anti-human IgG antibody and [ 125 I]-labeled protein A or protein G. A peptide derived from the MHC class II-associated invariant chain (CLIP, residues 87-101) was used as a negative control. In the direct binding assay, similar levels of binding were observed with immobilized MBP and with biotinylated MBP peptide captured on streptavidin-coated plates, confirming that the peptide was accessible for autoantibody binding (Table I) .
The strongest binding was observed with peptides from the L2 protein of human papillomavirus (type 7 and type 13), which were bound by purified autoantibodies from all 11 MS patients. Autoantibody binding to these papillomavirus peptides was strain-specific since only peptides from type 7 and 13 (which shared the VHFFK-I sequence with the MBP peptide) were bound by autoantibodies from all patients. In contrast, peptides from the L2 protein sequences of strains 40 and 32, in which K91 was substituted by arginine or histidine, were only bound by autoantibodies from patients H-K in whom peptide residue K91 was not as important for autoantibody binding as in patients A-G. The human papillomavirus type 7 peptide was previously examined for T cell recognition, and was found to activate a human MBP-specific T cell clone from an MS patient (24) .
The degree of antibody binding to the microbial peptides correlated with the number of amino acids in the epitope center that were identical to the MBP peptide. The peptides from the L2 protein of human papillomavirus (which bound best) were identical at six positions (VHFFK-I) with the MBP peptide, followed by two peptides from Bacillus subtilis and Clostridium cellulare (five-amino acid identity, FFKNI). Twelve peptides with four-amino acid identity (FFKN) showed a similar level of binding in a given patient (Table I) .
Autoantibody recognition of microbial peptides required sequence identity over a stretch of four or five amino acids. In contrast, only one of eight peptides (the human papillomavirus L2 protein peptide) that were previously found to activate human MBP-specific T cell clones, had obvious sequence homology with MBP; due to the degenerate MHC binding motif, only TCR contact residues in the center of the epitope had to be conserved (24) . This comparison indicated that amino acid identity in the center of the epitope was required for recognition of microbial peptides by autoantibodies, but not by MBPspecific T cell clones (24) .
Discussion
This study demonstrates that MBP-specific autoantibodies have a remarkably similar fine specificity for the immunodominant MBP peptide, as previously described MBP-specific T cell clones from patients with the MS-associated HLA-DR2 haplotype. The same 10-amino acid sequence represents the autoantibody epitope and the MHC binding/TCR contact residues of the T cell epitope. Both epitopes are centered on the H88-K91 segment, and F89 and K91 are key contact residues for both autoantibodies and T cell receptors (Fig. 3 ). An important difference between the autoantibody and the T cell epitope is that the FFK sequence has to be absolutely conserved for autoantibody binding. In the T cell epitope, the second phenylalanine in the FFK sequence is an MHC anchor residue that can be substituted by other hydrophobic amino acids. Also, the peptide required for optimal T cell stimulation is longer (13-15 amino acids) than that required for autoantibody binding (10 amino acids) (8) . The immunodominant MBP(82-100) region also contains an epitope for T cells restricted by DR4 and other DR antigens. In this epitope, the primary MHC anchor residue (F90) is shifted by three amino acids towards the COOH terminus of MBP (4). The MHC/ TCR contact residues of this epitope have not yet been defined in detail.
The immunodominant autoantibody epitope may be localized on a linear peptide segment of MBP, rather than on a conformation-sensitive epitope, because MBP is flexible due to the presence of many positively charged residues and the absence of disulphide bonds (29) . The major difference between the peptide segment that is bound by autoantibodies and the MHC-bound peptide that is recognized by TCRs is that MHC class II binding imposes a particular conformation on the pep- Residues that contributed to autoantibody binding were located in a 10-amino acid segment (flanked by proline 85 and proline 96). In seven of the MS cases, K91 was a key residue for autoantibody binding; in four cases, F89 and F90 were particularly important. The MHC/TCR contact residues for HLA-DR2 (DRB1*1501 and DRB1*1601) and HLA-DQ1-restricted T cell clones were located in the same 10-amino acid segment that represented the autoantibody epitope. In the T cell epitope H88, F89 and K91 were primary contact residues for MBP-specific TCRs (arrows up); V87 and F90 were MHC anchor residues (arrows down) (8, 22 ). An important difference between the antibody and the T cell epitope was that a 10-amino acid peptide was bound by autoantibodies while a longer peptide (13-15 amino acids) was required for optimal stimulation of MBP specific T cell clones (8) . Figure 2 . Fine specificity of MBP autoantibodies. A panel of 44 analog peptides with single amino acid substitutions in the VVHFFKNI sequence was tested for the ability to compete for autoantibody binding to immobilized MBP (patients A and K). In addition, six peptides with D -amino acid substitutions were examined. In both patients, substitution of F89, F90, and K91 (FFK) greatly reduced the ability of these peptides to compete for the binding of autoantibodies to immobilized MBP. For autoantibody binding, these residues had to be absolutely conserved since even conservative substitutions (for example, substitution of F90 and F91 by other aromatic residues or by aliphatic amino acids) greatly diminished autoantibody binding. The contribution of these peptide residues to autoantibody binding was confirmed using analog peptides with single amino acid substitutions by D -amino acids. (32, 24) . In solution, the MBP peptide may assume a helical conformation, either as an ␣-helix (3.6 residues/ turn) and/or as a 3 10 -helix (three residues/turn). Nuclear magnetic resonance analysis of short alanine peptides (16 or 17mers) indicated that peptides in aqueous solution prefer a 3 10 -helix; a 3 10 -helix may be a stable intermediate between a random coil and an ␣-helical conformation (random coil↔3 10 helix↔␣-helix) (33) . Microbial peptides that activate MBP-specific T cells and B cells may trigger an autoimmune response against MBP; the inflammatory response may be self-perpetuating after an infectious agent has been cleared (or has become latent) since MBP and other myelin proteins are released as the result of myelin destruction (25, 26) . Microbial peptides that are bound by affinity-purified MBP-specific autoantibodies were identified based on the antibody-binding motif; among these peptides, the strongest autoantibody binding was observed with a peptide from the human papillomavirus L2 protein, a minor capsid protein. Binding of the autoantibody to the native viral protein was not examined because human papillomavirus cannot be propagated in vitro (neither in primary cultures nor in established epithelial cell lines) (34) . The peptide segment, however, may be solvent-exposed because two charged residues (lysine and aspartic acid) are located in the center of the epitope.
The colocalization of the immunodominant T cell and B cell epitopes of MBP may be important in the autoimmune response against MBP in MS. Antigen-specific B cells are efficient antigen-presenting cells due to specific uptake of antigen via surface immunoglobulin (18, 19) . Antibody binding to antigen was also shown to modulate antigen processing in human B lymphoblastoid cells. A single bound antibody or its F(ab) fragment could simultaneously enhance the presentation of one T cell determinant of tetanus toxoid while strongly suppressing the presentation of a different T cell determinant. Both the suppressed and boosted determinants fell within an extended domain of antigen stabilized (or footprinted) by the antibody during proteolysis (35) . Binding by MBP-specific autoantibodies may protect the immunodominant T cell epitope from proteolytic degradation. MBP is very sensitive to proteolytic degradation, and a brain cathepsin D cleavage site is located in the center of the immunodominant epitope (between F89 and F90 in the FFK motif) (36) .
Since studies in the EAE model have demonstrated that systemic administration of soluble MBP peptides induces tolerance and reverses clinical disease (37, 38) , the immunodominant MBP peptide may be useful for the induction of both T cell and B cell tolerance to MBP in MS.
